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Resumo
O diabetes mellitus é uma condição crônica complexa que é uma das prin-
cipais enfermidades ao redor do mundo. Muitas evidências suportam que 
a hiperglicemia crônica conduz a uma série de eventos bioquímicos resul-
tando na produção de estresse oxidativo e danos neurológicos. Portanto, 
as terapias adjuvantes que utilizem compostos antioxidantes contra esta 
patologia têm sido sugeridas. O composto N-acetilcisteína (NAC) tem im-
portantes propriedades antioxidantes e neuromodulatórias. Portanto, con-
siderando que o estresse oxidativo e as disfunções colinérgicas têm sido 
associadas com a patogênese de diferentes complicações diabéticas, o ob-
jetivo deste estudo foi investigar o efeito da NAC sobre parâmetros de es-
tresse oxidativo e a atividade das enzimas acetilcolinesterase (AChE) e ami-
nolevulinato desidratase (ALA-D) em ratos normoglicêmicos e diabéticos. 
Os animais receberam 50 ou 200 mg/kg NAC por gavagem diariamente, 
durante 45 dias. Os resultados mostraram uma falta de uniformidade na 
atividade da AChE entre as quatro estruturas cerebrais. Embora nenhuma 
81–105, 2012
82
dose de NAC tenha produzido atividade hipoglicemiante significativa, a 
dose de 50 mg/kg de NAC reverteu parcialmente a perda de peso corporal 
dos diabéticos e foi efetiva em restaurar a atividade da ALA-D e o conteúdo 
de tióis não-protéicos no fígado, além de diminuir a carbonilação protéi-
ca sérica. A dose de 200 mg/kg de NAC apresentou alguns efeitos per se 
negativos em ambos os sistemas antioxidante e colinérgico. Portanto, con-
cluímos que a administração oral de 50 mg/kg de NAC durante 45 dias foi 
efetiva, removendo parcialmente a perda de peso dos diabéticos e tornando-
-se efetiva na restauração da atividade da ALA-D e conteúdo de NPSH no 
fígado, bem como diminuindo a carbonilação de proteína do soro em ratos 
diabéticos induzidos com aloxano. Contudo, futuros estudos são necessá-
rios para melhorar a utilização da NAC em terapias antioxidantes a fim de 
compreendermos os mecanismos de ação da NAC.
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Abstract
Diabetes mellitus is a complex chronic condition which is a major source of 
ill health all over the world. Extensive evidence supported that chronic hyper-
glycemia leads to a series of biochemical events resulting in the production 
of oxidative stress and neurological impairments. In view of this, adjuvant 
therapies using antioxidant compounds against this pathology have been su-
ggested. N-acetylcysteine (NAC) is a compound with important antioxidant 
and neuromodulatory properties. Therefore, considering that the oxidative 
stress and cholinergic dysfunctions have been associated with the pathogene-
sis of different diabetic complications, the aim of this study was to investigate 
the effect of NAC on oxidative stress parameters and acetylcholinesterase 
(AChE) and aminolevulinate dehydratase (ALA-D) activities of normoglyce-
mic and diabetic rats. The animals received 50 or 200 mg/kg NAC by gavage 
daily for 45 days. The results showed a lack of uniformity in AChE activity 
among the four cerebral structures. While neither dose of NAC produced sig-
nificant hypoglycemic activity, 50 mg/kg NAC partially  reversed the weight 
loss of diabetics and was effective in restoring ALA-D activity and non-pro-
tein thiol content in liver, and in diminishing serum protein carbonylation. 
The dose of 200 mg/kg NAC presented some negative effects per se in both 
the antioxidant and cholinergic systems. Therefore, we conclude that oral 
administration of 50 mg/kg NAC during 45 days was effective partially rever-
sing the loss weight of diabetics and being effective in restore ALA-D activity 
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and NPSH content in liver, as well as diminishing serum protein carbonyla-
tion in alloxan-induced diabetic rats. However, future studies are necessary to 
improve the use of NAC in antioxidant therapies in order to understand the 
mechanisms of NAC action..
Keywords: AChE, diabetes mellitus, NAC, oxidative stress.
Introduction
Diabetes mellitus, a group of chronic metabolic disorders affecting millions 
of people around the world, is characterized by hyperglycemia that affects 
carbohydrate, fat and protein metabolisms resulting from impairment in 
insulin secretion, insulin action, or both (American Diabetes Association 
Diagnosis and Classification of Diabetes Mellitus, 2006). This disease in 
humans and experimental models is associated with neurochemical, neuro-
physiological, and behavioral modifications as well as vascular disturbances 
in brain function and integrity (Biessels et al., 2002; Mazzanti et al., 2006). 
In this context, our research group have demonstrated that both purinergic 
and cholinergic neurotransmission is impaired in diabetic rats by altering 
ecto-nucleoside triphosphate phosphohydrolase, ecto-5’-nucleotidase and 
acetylcholinesterase (AChE; E.C. 3.1.1.7) activities (Schmatz et al., 2009a,b,c). 
 AChE is an important regulatory enzyme that promotes the hydrolysis 
of the neurotransmissor acetylcholine (ACh) in the synaptic cleft of choli-
nergic synapses and neuromuscular junctions (Mazzanti et al., 2006) and 
has an essential role in regulating many vital functions, such as learning, 
memory, cortical organization of movement and cerebral blood flow con-
trol (Appleyard, 1992). The cholinesterases and their activities are conside-
red a good indicator of cholinergic activity (Mazzanti et al., 2006; Schmatz 
et al., 2009a,b,c).       
Moreover, heme biosynthesis is impaired in a group of diseases named 
porphyrias, mainly porphyria cutanea tarda, in which a higher incidence of 
diabetes mellitus than in the general population has been observed. d-Ami-
nolevulinate dehydratase (d-ALA-D), an enzyme in the heme biosynthe-
sis pathway, is essential for all aerobic organisms and catalyses the asym-
metric condensation of two molecules of 5-aminolevulinic acid (d-ALA) 
to form the monopyrrole porphobilinogen (PBG) (Fernández-Cuartero et 
al., 1999). Moreover, it is a marker for oxidative stress because its active 
sulfhydryl group renders it highly sensitive to pro-oxidant elements which 
impair its function (Jacques-Silva et al., 2001).
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Oxidative stress has been associated with the pathogenesis of different 
diabetic complications (Elias et al., 2008; Ha et al., 2008; Hamdem et al., 
2009). Several studies have reported that enzymatic and/or non-enzymatic 
antioxidant systems are impaired in diabetes (Barbosa et al., 2008; Ham-
dem et al., 2009). The prooxidant-antioxidant imbalance in diabetes may be 
due to acceleration of some cellular reactions that lead to increased radical 
production, such as non-enzymatic protein glycosylation, glucose oxidation 
and increased sorbitol pathway, or reduced antioxidant defense potential 
(Ha et al., 2008). Also, advanced glycation end-products (AGEs) have been 
hypothesized to be associated with an excess of glucose and to be formed 
via oxidative denaturation (Miyata & Dan, 2008). In view of this, treatment 
with antioxidants, antihyperglycemics and cholinergic agonists are repor-
ted to produce beneficial effect in diabetic state. In fact, treatment with the 
antioxidant compound berberine prevents the changes in oxidative stress 
and AChE activity, and consequently memory impairment in diabetic rats 
(Bhutada et al. (2011). Sefi et al. (2010) demonstrated the antioxidant pro-
perties of Artemisia campestris leaf extract on hyperlipidemia, AGEs and 
oxidative stress in alloxan-induced diabetic rats preventing diabetic com-
plications. Punithavathi et al. (2011) reported antihyperglycaemic, antilipid 
peroxidative and antioxidant effects of gallic acid on diabetic rats induced 
by streptozotocin. Moreover, our group and others recently demonstrated 
that the antioxidant resveratrol and the medicinal plant ginger have a pro-
tector effect against hepatic and renal damage induced by oxidative stress 
in diabetic rats (Shanmugam et al., 2011; Schmatz et al., 2012). 
The induction of experimental diabetes in rats using chemicals such as 
alloxan and streptozotocin is very convenient and simple. Alloxan causes 
a massive reduction in insulin release, by the destruction of the b-cells of 
the Langerhans islets, inducing hyperglycemia (Szkudelski, 2001). N-ace-
tylcysteine (NAC) can effectively and specifically inhibit activation of the 
pancreatic nuclear factor NFkB and is able to attenuate the severity of the 
disease (Ho et al., 1999). NAC act as an antioxidant compound by directly 
to scavenge hydrogen peroxide (H
2
O
2
), hydroxyl free radicals (•OH) and hy-
pochloric acid (HOCl) in vitro, and it decreases free radical levels acting as 
a precursor of glutathione (GSH) to facilitate intracellular GSH synthesis 
(Sagristá et al., 2002). In fact, Dean et al. (2004) demonstrated that NAC 
crosses the blood brain barrier, replenishes brain GSH, enhances neuroge-
nesis of neuronal stem cells and promotes neuronal survival in a rat model. 
UFSM, 34(1)
85
Furthermore, NAC has potential to reverse cognitive dysfunction and oxi-
dative stress induced by bisphenol A in rats (Jain et al., 2011). This potential 
antioxidant and neuroprotective effects of NAC have been demonstrated 
in a variety of neurodegenerative disease models (Andreassen et al., 2000; 
Berk et al., in press). Moreover, our group recently published that NAC 
prevents memory deficits, the decrease in AChE activity , the hematological 
impairments, and oxidative stress in rats exposed to cadmium (Gonçalves 
et al., 2010; Gonçalves et al. in press). 
Thus, the objective of the present study was to contribute to a better 
understanding of the NAC effects on diabetes because of its well-known 
antioxidant characteristics. In order to obtain these results, normoglycemic 
and alloxan-induced rats were used to evaluate the effect of NAC on AChE 
and ALA-D activities and their relation to antioxidant system. 
Material and methods
Chemicals 
Acetylthiocholine iodide, 5,5’-dithio-bis-2-nitrobenzoic acid (DTNB), tris-
-(hydroxymethyl)-aminomethane GR, Coomassie brilliant blue G and thio-
barbituric acid (TBA) were obtained from Sigma Chemical Co. (St. Louis, 
MO, USA). Bovine serum albumin was purchased from Reagen. N-ace-
tylcysteine was obtained from Beg (São Paulo, SP, Brazil) with 99.1% of 
purity. All other reagents used in the experiments were of analytical grade 
and of the highest purity.
Animals
Adult male Wistar rats (150 – 230 g) obtained from the Central Animal House 
of the Federal University of Santa Maria (Santa Maria, RS, Brazil) were used 
in this experiment. The animals were maintained at a constant temperature 
(23 ± 1ºC) on a 12 hours light/dark cycle with free access to food and water. 
All animal procedures were approved by the Animal Ethics Committee from 
UFSM (protocol under number: 23081.003049/2006-61).
Experimental induction of diabetes 
Diabetes was induced, in overnight-fasted rats, by a single intraperitoneal 
injection (i.p.) of alloxan monohydrate in a fresh solution of 0.05 M sodium 
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 citrate (pH 4.5) at a dose of 150 mg/kg body weight. Since alloxan is capable of 
producing fatal hypoglycemia as a result of massive pancreatic insulin release, 
rats were treated with 20 % glucose solution (2 ml) orally after 6h of induction 
with alloxan. The rats were then kept for the next 24 h on 5 % glucose solution 
bottles as a substitute for water in their cages to prevent hypoglycemia. 
The diabetic state was checked and confirmed 15 days after induction. 
Blood samples were collected from the caudal vein and glucose was mea-
sured with a portable glucometer (ADVANTAGE, Boehringer Mannheim, 
MO, USA). Only animals with fasting glycemia over 200 mg/dl were con-
sidered diabetic and selected for the experiment. Animals described as fas-
ting were deprived of food but allowed free access to drinking water. 
Treatment
Animals were randomly divided into six different groups (6 rats per group). 
The treatment groups can be summarized as follows: group I, control/saline; 
group II, control/NAC50 (50 mg NAC/kg body weight), group III, control/
NAC200 (200 mg NAC/kg body weight); group IV, diabetic/saline; group V, 
diabetic/NAC50 (50 mg NAC/kg body weight); group VI, diabetic/NAC200 
(200 mg NAC/kg body weight). The choice of the doses of 50 and 200 mg/kg 
of NAC was made based in several studies that used these same doses of NAC 
and obtained beneficial results (Sadowska et al., 2007 and references therein). 
N-acetylcysteine (NAC) was freshly prepared in saline and was administered 
(1 mL/kg) by gavage daily, seven times/week, for 45 days between 9 and 11 a.m. 
At the onset (15 days after alloxan or saline injection) and at the end of 
the experiment (45 days after NAC treatment) the body weight of rats were 
measured. At the end of the experimental period, the rats were deprived of 
food overnight and then euthanized by heart puncture. After that, the liver, 
kidney and brain were carefully removed. The cranium was opened and 
the structures were gently removed and separated into cerebellum (CE) 
cerebral cortex (CC), striatum (ST) and hippocampus (HP).
Acetylcholinesterase assay (AChE; E. C. 3.1.1.7 )
The four brain structures selected for the experiment (CE, CC, ST and 
HP) were maintained refrigerated in a solution of 10 mM Tris-HCl, pH 
7.4, on ice. The tissues were homogenized in a glass potter in Tris-HCl so-
lution at a proportion of 1:10 (w/v) and then centrifuged at 3500 rpm for 
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10 min to yield a supernatant that was used for the enzyme assay. AChE ac-
tivity was determined by a modification of the spectrophotometric method of 
Ellman et al. (1961). The assay medium (2 ml final volume) contained 100 mM 
potassium phosphate buffer (pH 7.5) and 1 mM 5,5’-dithio-bis-2-nitrobenzoic 
acid (DTNB). One hundred microliters of supernatant from the brain structu-
res were pre-incubated for 2 min at 25°C. The reaction was initiated by adding 
200 ml of 0.8 mM acetylthiocholine iodide (AcSCh) as the substrate. After 
pre-incubation, the reaction speed was measured by increasing absorbance to 
412 nm. The enzyme activity was expressed in mmol AcSCh/h/mg protein.
d  -  aminolevulinic acid dehydratase assay (ALA-D; 
E.C. 4.2.1.24)
ALA-D activity of livers and kidneys were assayed according to the method 
of Sassa (1982) by measuring the rate of porphobilinogen (PBG) formation, 
except that in all enzyme assays the final concentration of ALA was 2.2 mM. 
Samples were homogenized in 50 mM Tris-HCl (pH 7.5) at a proportion of 
1:10 (w/v) and centrifuged at 3000 rpm for 10 min. An aliquot of 200 ml 
of supernatant was incubated during 0.5 h for liver and 1 h for kidney at 
37°C. The reaction was stopped by addition of 250 ml of trichloroacetic acid 
(TCA). The reaction product was determined using modified Ehrlich’s rea-
gent at 555 nm. ALA-D activity was expressed as nmol PBG/mg protein/h.
Catalase assay (CAT; E.C. 1.11.1.6)  
For the CAT assay, rat livers and kidneys were homogenized in 50 mM po-
tassium phosphate buffer, pH 7.5, at a proportion of 1:9 (w/v) and 1:5 (w/v), 
respectively. The homogenate was centrifuged at 3000 rpm for 10 min to 
yield a supernatant that was used for the enzyme assay. CAT activity was 
measured by the method of Nelson and Kiesow (1972). The reaction mix-
ture contained 50 mM potassium phosphate buffer (pH 7.5), 10 mM H
2
O
2
 
and 20 ml of the supernatant. The rate of H
2
O
2
 reaction was monitored at 
240 nm for 2 min at room temperature. Enzyme activity was expressed as 
DE/min/mg protein.
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Ascorbic acid (AsA) and Non-protein thiol groups 
(NPSH) contents
For determination of AsA and NPSH contents, livers and kidneys were 
homogenized in 50 mM Tris-HCl buffer, pH 7.5, at a proportion of 
1:10 (w/v). The homogenate was centrifuged at 3000 rpm for 10 min. The 
supernatant was precipitated in a cold 10% TCA solution at a proportion of 
1:1 (v/v) and submitted to the same centrifugation again. This supernatant 
was then used for analysis.
Ascorbic acid determination was performed as described by Jacques-
-Silva et al. (2001). An 300 ml aliquot of sample in a final volume of 575 ml 
of solution was incubated for 3 h at 37°C then 500 ml H
2
SO
4
 65% (v/v) was 
added to the medium. The reaction product was determined using a color re-
agent containing 4.5 mg/ml 2,4-dinitrophenylhydrazine (DNPH) and CuSO
4
 
(0.075 mg/ml). AsA levels were expressed as mg ascorbic acid/g tissue.
NPSH was measured spectrophotometrically with Ellman’s reagent 
(1959). An aliquot of 100 ml for liver and 200 ml for kidney in a final volume 
of 900 ml of solution was used for the reaction. The reaction was read at 412 
nm after the addition of 10 mM DTNB (0.05 ml). A standard curve using 
cysteine was added to calculate the content of thiol groups in samples, and 
was expressed as µmol SH/g tissue. 
Carbonylation 
Reaction with DNPH is a standard method for detecting carbonyl groups 
that can be used to follow changes on protein oxidation. The carbonylation of 
serum proteins was determined by modifications of Levine et al. (1990) me-
thod. Firstly, from 1 ml of serum, the proteins were precipitated using 0.5 ml 
of 10% TCA and centrifuged at 5000 rpm for 5 min and the supernatant was 
discarded. One half milliliter of 10 mM DNPH in 2 M HCl was added to this 
protein precipitate and incubated at room temperature for 30 min. During 
the incubation time the samples were mixed vigorously every 15 min. After 
the incubation time, 0.5 ml of 10% TCA was added to the protein precipitate 
and centrifuged at 5000 rpm for 5 min. After discarding the supernatant, 
precipitates were washed twice with 1 ml ethanol/ethylacetate (1:1), each time 
centrifuging out the supernatant in order to remove the free DNPH. The 
precipitate was dissolved in 1.5 ml of protein dissolving solution (2 g SDS and 
50 mg EDTA in 100 ml 80 mM phosphate buffer, pH 8.0) and incubated 
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at 37°C water bath for 10 min. The color intensity of the supernatant was 
measured using a spectrophotometer at 370 nm against 2 M HCl. Carbonyl 
content was calculated by using the molar extinction coefficient (21 X 103 L/
mol cm) and results were expressed as nmol carbonyl/mg protein.
Protein determination
In all the enzyme preparations, protein was measured according to Bra-
dford (1976) using bovine serum albumin as standard. For brain tissues, 
the protein was determined previously and adjusted for each structure: 
CE (0.5 mg/ml), CC (0.7mg/ml), HP (0.8 mg/ml) and ST (0.4 mg/ml).
Statistical analysis
All data were expressed as mean ± S.E.M. of four to six observations per 
group and statistically assessed by two-way ANOVA for fasting glucose 
levels and body weight and by one-way ANOVA for other parameters 
followed by Duncan’s multiple range test when the F test was significant 
(P < 0.05) to determine differences among the groups. 
 
Results
Blood glucose levels and rat body weights
The effect of different doses of NAC on fasting blood glucose levels and rat 
body weights of both control and diabetic rats at the onset (15 days after alloxan 
or saline injection) and the end of the experiment (45 days after NAC treat-
ment) is given in Table 1. In all groups prior to alloxan administration, the 
basal levels of blood glucose were not significantly different (data not shown). 
The fasting blood glucose levels of the diabetic/saline group were significantly 
higher than those of the control/saline group at the onset and at the end of 
the experiment (P < 0.05). The treatment with different doses of NAC in both 
control and diabetic rats did not produce any hypoglycemic activity (P < 0.05). 
The control/saline group showed a 40% increase in body weight at the 
end of the experiment. On the other hand, the body weight of diabetic/sali-
ne and diabetic/NAC200 was significantly lower at the end of the study in 
comparison to control/saline group (P < 0.05). Treatment with 50 mg/kg of 
NAC decreased the diabetes-induced reduction in body weight (P < 0.05).
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Table 1. The effect of different doses of N-acetylcysteine (NAC) on fasting blood glucose levels 
and body weight in control and diabetic rats at the onset (15 days after alloxan or saline injec-
tion) and the end of the experiment (45 days after NAC treatment).
Values are expressed as mean ± S.E.M. n=4-6 observations per group. 
Different capital letters indicate significant differences among the groups 
(p<0.05). Different lower case letters indicate significant differences betwe-
en the onset and the end of the experiments (P < 0.05).
AChE activity in brain
The results obtained for AChE activity in brain structures are presented in Fi-
gure 1. As can be observed, in CE there was no significant alteration in AChE 
activity among the groups (P > 0.05) (Figure 1A). In CC, AChE activity was 
significantly decreased in the diabetic/NAC50 and diabetic/NAC200 groups 
(P < 0.05) compared to the control/saline and diabetic/saline groups (Figu-
re 1B). On the other hand, treatment with NAC per se significantly increased 
ST AChE activity in the control/NAC200 group (P < 0.05) when compared 
to the control/saline group (Figure 1C). Oral administration of NAC had no 
significant effect on HP AChE activity of controls and diabetic rats compared 
to the control/saline and diabetic/saline groups, but there was a significant 
reduction in AChE activity in this structure in the diabetic/saline group when 
compared to the control/saline group (Figure 1D).   
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Groups Blood glucose levels (mg/dL) Rat body weight (g)
Onset End Onset End
control/saline 64.0 ± 3 Ca 69.3 ± 3 Ba 204.7 ± 5 Ab 292.6 ± 9 Aa
control/NAC50 61.4 ± 2 Ca 70.0 ± 3 Ba 202.2 ± 9 Ab 283.8 ± 12 Aa
control/NAC200 60.5 ± 4 Ca 71.5 ± 2 Ba 215.6 ± 11 Ab 291.9 ± 17 Aa
diabetic/saline 395.5 ± 27 Aa 347.0 ± 46 Aa 161.5 ± 9 Ba 161.5 ± 10 Ca
diabetic/NAC50 307.1 ± 21 Ba 303.8 ± 12 Aa 215.4 ± 10 Aa 224.0 ± 10 Ba
diabetic/NAC200 294.3 ± 13 Ba 298.7 ± 17 Aa 196.9 ± 11 Aa 180.3 ± 15 Ca
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Figure 1. Effect of 45 days of oral treatment with N-acetylcysteine (NAC) on AChE activity 
in the cerebellum (A), cerebral cortex (B), striatum (C) and, hippocampus (D). Values are 
expressed as mean ± S.E.M. n=4-6 observations per group. Different capital letters indicate 
significant differences among the groups (P < 0.05).
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Pro-oxidant parameters: l iver and kidney ALA-D 
activity and serum carbonyl groups    
Figure 2 illustrates tissue ALA-D activity and serum carbonyl groups of con-
trol and experimental animals. Liver ALA-D activity showed a 35% decrease 
in the diabetic/saline group (P < 0.05) compared to the control/saline group 
(Figure 2A). This reduction in hepatic ALA-D activity did not occur when 
NAC was administered after alloxan treatment for 45 days (P < 0.05). On the 
other hand, there were no significant differences among the control and the 
alloxan-induced rats in kidney ALA-D activity (P < 0.05) (Figure 2B). 
There was a significant increase of 55% in the serum content of car-
bonyl in the diabetic/saline group (P < 0.05) compared to the control/saline 
group (Figure 2C). This increase in carbonyl did not occur when 50 mg/kg 
of NAC was administered in diabetic rats and it was partially reversed by 
200 mg/kg of NAC (P > 0.05).
Figure 2. Effect of 45 days of oral treatment with N-acetylcysteine (NAC) on ALA-D activity 
in liver (A) and kidney (B) and on serum protein carbonylation (C). Values are expressed as 
mean ± S.E.M. n=4-6 observations per group. Different capital letters indicate significant 
differences among the groups (P < 0.05).
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Antioxidant parameters: CAT activity and AsA and 
NPSH content in kidney and l iver tissues 
CAT activity and AsA and NPSH contents in kidney and liver tissues are 
shown in Figure 3. Liver CAT activity was significantly decreased in the 
diabetic/saline, diabetic/NAC50 and diabetic/NAC200 groups (P < 0.05) 
compared to the control/saline group (Figure 3A). Kidney CAT activity de-
creased only in the diabetic/NAC200 group (P < 0.05) compared to the 
control/saline group (Figure 3B). Administration of NAC caused a decrease 
in CAT activity in both liver and kidney of alloxan-induced rats (P < 0.05) 
compared to their respective control/NAC groups.   
There was a significant reduction in both liver and kidney AsA con-
tent in the diabetic/saline, diabetic/NAC50 and diabetic/NAC200 groups 
(P < 0.05) compared to the control/saline group (Figures 3C and D). Oral treat-
ment with NAC per se significantly decreased liver AsA content in the control/
NAC200 group (P < 0.05) when compared to the control/saline group. Admi-
nistration of NAC caused a decrease in AsA content in both tissues of alloxan-
-induced rats (P < 0.05) compared to their respective control/NAC groups.   
Liver NPSH content was significantly decreased in the diabetic/sali-
ne, diabetic/NAC50 and diabetic/NAC200 groups (P < 0.05) compared 
to the control/saline group (Figure 3E). Oral treatment with NAC per se 
significantly decreased liver NPSH content in the control/NAC200 group 
P < 0.05) when compared to the control/saline group. Kidney NPSH con-
tent was significantly increased in the diabetic/saline, diabetic/NAC50 and 
diabetic/NAC200 groups (P < 0.05) compared to the control/saline group 
(Figure 3F). While NAC administration had no significant effect on kid-
ney NPSH content of diabetic rats, there was a significant increase in liver 
NPSH content in the diabetic/NAC50 and diabetic/NAC200 groups (P < 
0.05) compared to the diabetic/saline group.
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Figure 3. Effect of 45 days of oral treatment with N-acetylcysteine (NAC) on CAT activity and 
AsA and NPSH content in liver (A, C and E, respectively) and kidney (B, D and F, respective-
ly). Values are expressed as mean ± S.E.M. n=4-6 observations per group. Different capital 
letters indicate significant differences among the groups (P < 0.05).
Discussion
This experimental study of alloxan-induced diabetes mellitus revealed that 
NAC did not produce significant hypoglycemic activity which is in accordan-
ce with Grover et al. (2000) since they postulated that the decrease in glucose 
levels differs in models of varying intensity of hyperglycemia. The antihyper-
glycemic effect of the drug is dependent upon the dose of the diabetogenic 
agent and therefore on the degree of b-cell destruction (Grover et al., 2000). 
We believe that NAC was ineffective to diminish blood glucose levels because 
of the severity of the diabetic model used in the present study (blood glucose 
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levels higher than 300 mg/dl) (Grover et al., 2000). Blood glucose levels in 
the body remain high when b-cells of the pancreas completely stop synthesi-
zing insulin, do not make enough insulin, or when the insulin that is made 
does not work correctly and, depending on the severity of the diabetes, the 
body can not function normally (Jain et al., 2002). 
Moreover, we have also observed that there was a gradual increase in 
body weight in the control groups while the diabetic groups did not show 
any significant effect on body weight throughout the treatment. Similar to 
previous studies (Prince et al., 1998; Schmatz et al., 2009a,b,c), in the pre-
sent study the body weight of the diabetic/saline group was lower at the end 
of the experiment when compared to the control/saline group as a result of 
innumerous disturbances in the diabetic metabolism. Interestingly, when 
50 mg/kg of NAC was administered to animals given alloxan, weight loss 
was partially reversed if compared to the diabetic/saline group, whereas at 
200 mg/kg this reverse of weight loss was not observed. 
Our current study showed a lack of uniformity in the profile of AChE ac-
tivity among the four cerebral structures. This fact may be related with the 
different cholinergic projections in the brain structures. For example, the 
cerebral cortex and hippocampus receive cholinergic projections from the 
nucleus basalis of Meynert, while the striatum has an intrinsic cholinergic 
circuit (Kaizer et al., 2005; Mazzanti et al., 2006). This may reflect hetero-
geneity in the central cholinergic system (Mazzanti et al., 2006) and could 
indicate the importance of the cholinergic via in these different brain re-
gions (Kaizer et al., 2005). AChE activity in cerebellum did not present any 
significant alteration among the groups while in cortex it was decreased in 
all the diabetic groups at both doses of NAC. On the other hand, in striatum 
200 mg/kg of NAC per se significantly increased AChE activity when com-
pared with the control/saline rats. Finally, while hippocampus AChE activi-
ty was decreased in the diabetic/saline group, both doses of NAC brought 
AChE levels near to those observed in the control/saline rats. Interestingly, 
the hippocampus plays a crucial role in synaptic plasticity (learning and 
memory) and in adult type 1 diabetic patients, modest reductions in mental 
efficiency have been reported repeatedly (Biessels et al., 2002). In fact, our 
group recently showed that resveratrol prevents memory deficits and the 
increase in AChE activity in streptozotocin-induced diabetic rats (Schmatz 
et al., 2009a,b). Also, Bhutada et al. (2011) demonstrated that isoquinoline 
alkaloid berberine might ameliorate the pathologies of diabetes-induced 
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cognitive dysfunction through inhibiting the AChE activity increased in the 
cortex and hippocampus of diabetic rats. AChE inhibition leads to an accu-
mulation of ACh, causing overstimulation of the receptors while AChE ac-
tivation leads to a fast ACh degradation and a subsequent downstimulation 
of ACh receptors (Mazzanti et al., 2006). These two mechanisms can pro-
mote adverse effects. However, the finding of new drugs that per se inhibit 
AChE activity is useful against Alzheimer complications and compounds 
that are able to activate this enzyme are a scientific tool to counteract orga-
nophosphate poisoning (Benzi & Morreti, 1998). According to Dash et al. 
(1991) the decreased activity of AChE observed in diabetic rats may be due 
to an early impairment of glucose oxidation and glucose transport, whi-
ch causes specific alterations in neurotransmitter levels, thereby affecting 
blood brain barrier transport and causing brain dysfunction. 
While in the present study there were no significant differences ob-
served in kidney ALA-D activity, liver ALA-D activity was decreased in dia-
betic/saline rats when compared to control/saline rats. It is interesting to 
note that treatment of diabetic rats with both doses of NAC interfered with 
alloxan action by preventing the inhibition of hepatic ALA-D activity. The 
differences between kidney and liver ALA-D responses may be explained 
by the fact that the liver takes up more glucose than the kidney (Sidossis 
et al., 1999) and, consequently, the high cytosolic steady-state level of glu-
cose in hepatocytes may favor the glycation of enzymes (ALA-D) and the 
production of additional free radicals associated with this type of reaction. 
Our tentative assumptions are supported by literature data showing that 
the glycation of proteins may occur intracellularly (Sidossis et al., 1999). 
Thus, the inhibition of ALA-D activity in liver of diabetic rats is supposed 
to be a consequence of glycation in the lysine residue from the active site 
of ALA-D, which is involved in the formation of the Schiff basis with the 
first molecule of ALA (Barbosa et al., 2008). Moreover, it has been reported 
that ALA-D inhibition can be due to the oxidation of sulfhydryl groups lo-
cated at its active center. In fact, similar to our results, Pivetta et al. (2006) 
demonstrated a positive correlation between inhibited ALA-D activity and 
decreased NPSH levels in liver of rats exposed to ethanol.
In addition, ALA-D inhibition may lead to an accumulation of ALA that 
can cause an overproduction of reactive oxygen species (ROS) (Jacques-Sil-
va et al., 2001) which, in turn, could exacerbate the oxidative stress caused 
by hyperglycemia. It has been suggested that diabetes mellitus is associated 
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with weakened cellular scavenging activity, which may increase vulnerabili-
ty to oxidative damage and the development of diabetic complications (Bar-
bosa et al., 2008; Elias et al., 2008; Ha et al., 2008; Hamdem et al., 2009).
This study showed a significant increase in the carbonylation of serum 
proteins in the diabetic groups compared to the control groups, indicating 
impairment of the protein structure (Jain et al., 2002; Levine, 2002). These 
groups are formed by oxidation of the side chains of lysine, proline, argi-
nine, and threonine residues (Levine, 2002). From the results obtained, it 
is clear that the oral administration of NAC produced a statistically signi-
ficant decrease in serum protein carbonylation in diabetic rats. Corrobora-
ting with our results Jain et al. (2002) reported that NAC can inhibit high 
glucose-induced oxidative damage to proteins in both lens cell cultures and 
isolated protein solution studies. 
It is well-known that glucose by itself as well as hyperglycemia-related in-
creased protein glycosylation are important sources of ROS as elevated gluco-
se causes slow but significant non-enzymatic glycosylation of proteins in dia-
betes (Miyata & Dan, 2008). Since the glycosylation of protein is an oxidative 
reaction, antioxidants should be able to prevent this reaction. We therefore 
verified catalase activity and AsA and NPSH contents in control and diabetic 
rats treated with NAC, a potent ROS scavenger and thiol group supplier.
In the present study, liver CAT activity was decreased in the diabetic/
saline group when compared to control/saline rats while no significant 
change was shown in kidney CAT activity in the diabetic/saline group. Oral 
administration of NAC at 50 or 200 mg/kg caused no amelioration in the 
diabetic status in either tissue. A decrease in liver CAT activity in the dia-
betic state may be due to inactivation caused by ROS and/or by a depletion 
of antioxidant enzymes in response to oxidative stress (Prince et al., 1998). 
This corroborates with Hamdem et al. (2009) and Prince et al. (1998) who 
reported inhibition in hepatic CAT activity in diabetics. However, there are 
controversial results in the literature concerning CAT activity. In diabetics, 
renal and hepatic CAT activities have been reported to decrease, increase or 
remain unaltered (Prince et al., 1998).  
Results of the current study showed that in both kidney and liver tis-
sues, AsA content was decreased in the diabetic/saline group compared to 
the control/saline group. Oral administration of NAC at 50 or 200 mg/kg 
caused no amelioration in the diabetic status in either tissue. In liver, NAC 
per se at 200 mg/kg significantly decreased AsA content when compared 
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to control/saline rats. Fay et al. (1990) reported that hyperglycemia and/
or hypoinsulinemia inhibit ascorbic acid cellular transport resulting in lo-
wer levels of this compound because as the chemical structure of ascorbic 
acid is similar to that of glucose, it shares the membrane transport system 
with glucose and hence competes with it for its transport. The decrease in 
AsA content may also be due to oxidation of AsA to dehydroascorbic acid 
(DHAA) or to the impaired regeneration of AsA from DHAA (Will & Byers, 
1996). According to Nonaka et al. (1991) because free radicals are normally 
neutralized by efficient systems in the body, including small antioxidant 
molecules such as AsA, increased requirements to neutralize free radicals 
may cause AsA concentrations to fall below normal in diabetic subjects. 
Moreover, it has been suggested that people with diabetes mellitus are ex-
posed to more oxidative stress because they have lower ascorbic acid con-
centrations than people without this disease (Sardesai, 1995). 
In our present study, the NPSH content of diabetic groups was decrea-
sed in liver and increased in kidney when compared to control/saline rats. 
As reported above, the liver takes up more glucose than the kidney and it 
may contribute to major liver damage. Glutathione (GSH), the main cellu-
lar thiol compound, has a variety of functions in bioreduction and detoxi-
fication processes. Our results suggest that increased GSH levels in the 
kidney of diabetic rats may function as an antioxidant defense as has been 
observed by our research group in patients after an ischemic event or at the 
beginning of tumor development (Maldonado et al., 2006; Corrêa et al., 
2008). GSH, when not completely used as substrate by glutathione pero-
xidase in the GSH cycle, may increase inside the cells. The higher kidney 
GSH levels in diabetic rats when compared to the controls may be a result 
of the depressed enzymatic activity of glutathione peroxidase or possibly 
because of a relative deficiency in the glutathione peroxidase cofactor se-
lenium (Campolo et al., 2007). Moreover, in liver, NAC per se at 200 mg/
kg caused a decrease in hepatic NPSH content in relation to the controls. 
It is interesting to note that both doses of NAC restored NPSH content in 
liver to near normal levels and these findings are similar to data presented 
by Fernández-Cuartero et al. (1999) who reported that GSH prevents the 
oxidation of ALA-D and concluded that a decrease of GSH levels would also 
explain the diminished activity of ALA-D in diabetic patients. 
Taken together, the results of this study showed that NAC did not pro-
duce significant hypoglycemic activity and that 50 mg/kg NAC partially 
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reversed the loss weight of diabetics and was effective in restoring ALA-D 
activity and NPSH content in liver, as well as in diminishing serum protein 
carbonylation.  However, at the dose of 200 mg/kg, some negative per se 
effects were observed in both antioxidant and cholinergic systems. In fact, 
Cotgreave (1997) reported that NAC in vivo failed to provide significant 
antioxidant effects, presumably due to its low lipid solubility and tissue 
distribution. In accordance, Sagristá et al. (2002) proposed a mechanism 
for the dual antioxidant and prooxidant behavior of NAC and GSH in an in 
vitro situation, suggesting that the iron-mediated oxidative metabolism of 
thiols may account for their prooxidant action. Ritter et al. (2004a,b) indi-
cated that the addition of deferoxamine (DFX) could increase the therapeu-
tic effects of NAC for sepsis and for a severe hepatic failure model probably 
because of the decrease of NAC oxidation and Fenton chemistry. 
Conclusions
In view of this, we conclude that oral administration of 50 mg/kg NAC 
during 45 days was effective partially reversing the loss weight of diabetics 
and being effective in restore ALA-D activity and NPSH content in liver, as 
well as diminishing serum protein carbonylation in alloxan-induced diabe-
tic rats. However, future studies are necessary to better use of NAC in an-
tioxidant therapies in order to understand the mechanisms of NAC action. 
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